➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
AstraZeneca
Boehringer Ingelheim
McKesson
Medtronic

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,716,814

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,716,814 protect, and when does it expire?

Patent 6,716,814 protects BALCOLTRA and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 6,716,814
Title: Enhancing solubility of iron amino acid chelates and iron proteinates
Abstract:A method of enhancing the solubility of iron amino acid chelates and iron proteinates is disclosed. This is accomplished by mixing an effective amount of an organic acid solubilizing agent into existing iron amino acid chelates or iron proteinates. The iron amino acid chelates and iron proteinates may have a ligand to metal molar ratio from about 1:1 to 4:1, preferably 2:1 to 3:1.
Inventor(s): Ericson; Clayton (Morgan, UT), Ashmead; H. DeWayne (Fruit Heights, UT)
Assignee: Albion International, Inc. (Clearfield, UT)
Application Number:09/931,397
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,716,814
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 6,716,814

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avion Pharms BALCOLTRA ethinyl estradiol; levonorgestrel TABLET;ORAL 208612-001 Jan 9, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,716,814

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002331603   Start Trial
Brazil 0212399   Start Trial
Canada 2457584   Start Trial
China 1264428   Start Trial
China 1555228   Start Trial
Spain 2303739   Start Trial
United Kingdom 0403792   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Dow
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.